{"disease":{"id":"growth-hormone-deficiency-in-children","name":"growth hormone deficiency in children"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00960128","title":"Observational Prospective Study on Patients Treated With Norditropin®","phase":"","overall_status":"COMPLETED","enrollment_count":21249,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT03972345","title":"Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in Patients With Growth Hormone Deficiency (GHD) and Born Small for Gestational Age (SGA)","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":750,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT03672617","title":"Validation of a Questionnaire That Identifies the Reasons for Non-adherence to Existing Growth Hormone Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":321,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT07126288","title":"Evaluating the Efficacy and Safety of GB08 Injection in Pediatric Patients With Growth Hormone Deficiency","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":268,"lead_sponsor_name":"Shenzhen Kexing Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT02580032","title":"Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)","phase":"","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT06109935","title":"Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":200,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT03811535","title":"A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT00567385","title":"Liquid Somatropin Formulation in Children With Growth Hormone Deficiency","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":176,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT01563926","title":"Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":168,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT04970654","title":"A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":110,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT01514500","title":"First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT01502124","title":"Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT02616562","title":"Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT03186495","title":"Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT03212131","title":"Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT01973244","title":"A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false}],"total":16},"guidelines":[],"source":"Drug Landscape verified database"}